Cellectis's CAR-T Therapy Lasme-cel Receives FDA RMAT Designation for r/r B-ALL
CLLS has more than doubled off its 52-week low of $1.327.
Summary
Cellectis's lead allogeneic CAR-T therapy, lasme-cel, received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), signaling potential for expedited development.
Key Events · Product Development and Regulatory · CLLS
-
FDA RMAT Designation Granted
Cellectis's CD22-targeting allogeneic CAR-T cell therapy, lasme-cel, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
-
Potential for Expedited Development
The RMAT designation acknowledges the therapy's potential to address an unmet medical need and strengthens the company's dialogue with the FDA as it advances lasme-cel through its pivotal program.
-
Phase 1 Data Presentation
Final Phase 1 data from the BALLI-01 trial supporting the designation will be presented in an oral session at the 2026 Congress of the European Hematology Association (EHA) on June 13.
-
Pivotal Phase 2 Enrollment Open
The pivotal Phase 2 of the BALLI-01 trial is currently open for enrollment, indicating progress towards potential market authorization.
Analysis · CLLS · Life Sciences
The FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for lasme-cel is a significant positive development for Cellectis. This designation is granted to therapies that address unmet medical needs and have the potential to expedite development and review, which is crucial for a clinical-stage biotechnology company. It validates the promising efficacy and safety profile observed in Phase 1 data and strengthens the company's regulatory pathway for this key allogeneic CAR-T product candidate.
At the time of this filing, CLLS was trading at $3.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $217.9M. The 52-week trading range was $1.33 to $5.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.